Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artelo Biosciences, Inc. (NASDAQ: ARTL) announced its participation in the H.C. Wainwright Annual Global Investment Conference, taking place virtually from September 14-16, 2020. CEO Gregory D. Gorgas is set to present on September 15 at 3:30 p.m. Eastern Time, with a live webcast available on the event platform. The company focuses on developing therapeutics targeting the endocannabinoid system to address unmet medical needs in various conditions such as cancer, pain, and anorexia. More details can be found on their website.
Details
News Market Reaction – ARTL
The recorded move for ARTL in the trading session of this news was -5.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference, being held virtually on September 14-16, 2020.
Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present on Tuesday, September 15th at 3:30 p.m., Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed here.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system and related pathways. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.